- Home
- TARS vs VRE Comparison
TARS vs VRE Comparison
Compare TARS & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- VRE
- Stock Information
- Founded
- TARS 2016
- VRE 1949
- Country
- TARS United States
- VRE United States
- Employees
- TARS N/A
- VRE N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- VRE Real Estate Investment Trusts
- Sector
- TARS Health Care
- VRE Real Estate
- Exchange
- TARS Nasdaq
- VRE Nasdaq
- Market Cap
- TARS 1.7B
- VRE 1.4B
- IPO Year
- TARS 2020
- VRE 1994
- Fundamental
- Price
- TARS $57.25
- VRE $15.25
- Analyst Decision
- TARS Strong Buy
- VRE Buy
- Analyst Count
- TARS 7
- VRE 5
- Target Price
- TARS $67.14
- VRE $19.20
- AVG Volume (30 Days)
- TARS 737.4K
- VRE 502.6K
- Earning Date
- TARS 08-06-2025
- VRE 07-23-2025
- Dividend Yield
- TARS N/A
- VRE 2.22%
- EPS Growth
- TARS N/A
- VRE N/A
- EPS
- TARS N/A
- VRE N/A
- Revenue
- TARS $295,521,000.00
- VRE $285,675,000.00
- Revenue This Year
- TARS $122.94
- VRE $4.75
- Revenue Next Year
- TARS $44.14
- VRE $3.57
- P/E Ratio
- TARS N/A
- VRE N/A
- Revenue Growth
- TARS 254.45
- VRE 5.04
- 52 Week Low
- TARS $25.14
- VRE $13.69
- 52 Week High
- TARS $57.60
- VRE $18.85
- Technical
- Relative Strength Index (RSI)
- TARS 79.79
- VRE 64.76
- Support Level
- TARS $53.15
- VRE $14.29
- Resistance Level
- TARS $55.17
- VRE $14.62
- Average True Range (ATR)
- TARS 2.03
- VRE 0.34
- MACD
- TARS 0.89
- VRE 0.12
- Stochastic Oscillator
- TARS 97.95
- VRE 91.12
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.